{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety\nand Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib\nin Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF\n(Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) That have a Suboptimal  Response to Ruxolitinib.","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-randomized-double-blind-placebo-controlled-study-of-the-safetyand-efficacy-of-navtemadlin-plus-ruxolitinib-versus-placebo-plus-ruxolitinibin-patients-with-primary-myelofibrosis-pmf-p\/#breadcrumbitem"}]}